Citius Oncology (CTOR)
Commercializing LYMPHIR for relapsed or refractory cutaneous T-cell lymphoma.
Something off on this page? Send us feedback.
Commercializes LYMPHIR, an IL-2-receptor-directed therapy for relapsed or refractory cutaneous T-cell lymphoma after prior systemic treatment. The portfolio centers on this first commercial product, launched in the United States, while Citius Pharmaceuticals remains majority owner and provides shared management services.
Commercializes LYMPHIR, an IL-2-receptor-directed therapy for adults with relapsed or refractory Stage I–III cutaneous T-cell lymphoma after prior systemic treatment. Launched in the United States in December 2025, LYMPHIR is the first commercial product and the portfolio’s central asset.
The company was formed by Citius Pharmaceuticals to hold LYMPHIR-related assets, and its Nasdaq-listed security resulted from a merger with TenX Keane Acquisition. Citius Pharmaceuticals remains the majority owner and provides shared management services.
Commercial revenue began with the LYMPHIR launch. Operating losses since inception, historical financing from Citius Pharmaceuticals, and limited post-launch revenue remain structural features of this early commercial stage.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 23, 2025 | Maxim Group | Upgrade | Target: — | Target: $6 |
| May 23, 2025 | Maxim Group | Downgrade |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $16.6M · Total debt $10.2M · Total assets $112.1M · Shareholders' equity $40.4M
- Revenue
- $1.5M
- Operating income
- −$8.7M
- Net income
- −$8.9M
No dividends on record.
| Institutions | 15.21% | 14.15M shares | |
|---|---|---|---|
| 20 holders · as of Jun 30, 2026 | |||
| Insiders | 6.58% | 6.12M shares | |
| 10 holders · as of Sep 23, 2025 | |||
| Other | 78.21% | 72.71M shares | |
| remainder | |||
92.98M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Armistice Capital, LLCInstitution | 9.36% | 8.71M | as of Jun 30, 2026 |
Bank of America Corp /DE/Institution | 4.12% | 3.84M | as of Jun 30, 2026 |
Leonard L. MazurInsiderdirector, officer: Chief Executive Officer | 1.83% | 1.70M | filed Sep 23, 2025 |
Myron Z. HolubiakInsiderdirector, officer: Secretary | 1.02% | 950,000 | filed Sep 23, 2025 |
Jaime BartushakInsiderofficer: Chief Financial Officer | 0.89% | 825,000 | filed Sep 23, 2025 |
Insider tradesForm 4
No open-market trades in the last 12 months.
- Pfizer
CD30 ADC for mycosis fungoides after systemic therapy
- Bristol-Myers Squibb
HDAC inhibitor for CTCL after one systemic therapy
- Merck
Oral HDAC inhibitor for CTCL after two systemic therapies
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Citius Oncology | $1.04 | −2.80% | $99.5M | — | — | 14.0 | — |
| Pfizer | $28.01 | +0.27% | $159.19B | 36.9 | 10.0 | 2.5 | +2.6% |
| Bristol-Myers Squibb | $61.73 | −0.84% | $127.16B | 13.7 | 9.7 | 2.6 | +5.7% |
| Merck | $147.28 | −2.41% | $372.73B | 120.7 | 17.1 | 5.6 | +5.1% |
| Median | 36.9 | 10.0 | 2.6 | +5.1% |